Acumen Pharmaceuticals Inc Net Assets
Acumen Pharmaceuticals Inc net assets. Based on the latest financial reports, Acumen Pharmaceuticals Inc (ABOS) has net assets worth $87.48 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($133.63 Million) and total liabilities ($46.15 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Acumen Pharmaceuticals Inc (ABOS) net asset momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $87.48 Million |
| % of Total Assets | 65.46% |
| Annual Growth Rate | N/A |
| 5-Year Change | -68.72% |
| 10-Year Change | N/A |
| Growth Volatility | 37.4 |
Net Assets of Acumen Pharmaceuticals Inc (2019–2025)
Net assets of Acumen Pharmaceuticals Inc from 2019 to 2025. This chart illustrates how Acumen Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. See debt-free asset ratio of Acumen Pharmaceuticals Inc to measure how much of total assets are equity-financed.
Annual Net Assets for Acumen Pharmaceuticals Inc (2019–2025)
The table below shows the annual net assets of Acumen Pharmaceuticals Inc from 2019 to 2025. For live market cap and overall valuation, see Acumen Pharmaceuticals Inc market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $70.43 Million | -61.26% |
| 2024-12-31 | $181.82 Million | -31.90% |
| 2023-12-31 | $266.97 Million | +41.42% |
| 2022-12-31 | $188.78 Million | -16.17% |
| 2021-12-31 | $225.18 Million | +1311.25% |
| 2020-12-31 | $-18.59 Million | -62.79% |
| 2019-12-31 | $-11.42 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Acumen Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 42682200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Acumen Pharmaceuticals Inc Net Assets Breakdown (December 2025)
Acumen Pharmaceuticals Inc net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $6.00K | 0.01% |
| Other Comprehensive Income | $83.00K | 0.12% |
| Other Components | $516.80 Million | 733.78% |
| Total Equity | $70.43 Million | 100.00% |
Acumen Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Acumen Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GiantStep Co. Ltd.
KQ:289220
|
$16.94 Million |
|
Korean Air Lines Co Ltd
KO:003495
|
$16.94 Million |
|
Mnc Sky Vision Tbk
JK:MSKY
|
$16.95 Million |
|
88 Energy Ltd
AU:88E
|
$16.95 Million |
|
BPM Minerals Ltd
AU:BPM
|
$16.93 Million |
|
Murano Global Investments PLC Ordinary Shares
NASDAQ:MRNO
|
$16.92 Million |
|
Dong Il Steel MFG Co Ltd
KO:002690
|
$16.89 Million |
|
Gotland Rederi AB Series B
ST:GOTL-B
|
$16.89 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Acumen Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 181,816,000 to 70,430,000, a change of -111,386,000 (-61.3%).
- Net loss of 121,335,000 reduced equity.
- Share repurchases of 73,000 reduced equity.
- Other comprehensive income increased equity by 131,000.
- Other factors increased equity by 9,891,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-121.33 Million | -172.28% |
| Share Repurchases | $73.00K | -0.1% |
| Other Comprehensive Income | $131.00K | +0.19% |
| Other Changes | $9.89 Million | +14.04% |
| Total Change | $- | -61.26% |
Book Value vs Market Value Analysis
This analysis compares Acumen Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.20x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-0.40 | $0.23 | x |
| 2020-12-31 | $-0.65 | $0.23 | x |
| 2021-12-31 | $5.88 | $0.23 | x |
| 2022-12-31 | $4.65 | $0.23 | x |
| 2023-12-31 | $5.49 | $0.23 | x |
| 2024-12-31 | $3.03 | $0.23 | x |
| 2025-12-31 | $1.16 | $0.23 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Acumen Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -172.28%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.74x
- Recent ROE (-172.28%) is below the historical average (-45.08%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -465.94% | 0.23x | 0.00x | $-6.76 Million |
| 2020 | 0.00% | -510.10% | 0.03x | 0.00x | $-5.47 Million |
| 2021 | -44.68% | -7005.99% | 0.01x | 1.02x | $-123.12 Million |
| 2022 | -22.70% | 0.00% | 0.00x | 1.04x | $-61.73 Million |
| 2023 | -19.62% | 0.00% | 0.00x | 1.16x | $-79.07 Million |
| 2024 | -56.28% | 0.00% | 0.00x | 1.31x | $-120.51 Million |
| 2025 | -172.28% | 0.00% | 0.00x | 1.74x | $-128.38 Million |
Industry Comparison
This section compares Acumen Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $147,108,682
- Average return on equity (ROE) among peers: -12.54%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Acumen Pharmaceuticals Inc (ABOS) | $87.48 Million | 0.00% | 0.53x | $16.93 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $26.78 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $3.53 Billion |
| Abeona Therapeutics Inc (ABEO) | $-5.83 Million | 0.00% | 0.00x | $243.03 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $1.41 Billion |
| Arbutus Biopharma Corp (ABUS) | $40.92 Million | 73.18% | 0.29x | $768.65 Million |
| ABVC Biopharma Inc (ABVC) | $29.08K | -111.02% | 1.35x | $26.26 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $7.74 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $182.13 Million | -20.84% | 0.04x | $3.54 Billion |
About Acumen Pharmaceuticals Inc
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement… Read more